(4R)-4-methyl-1,3-oxazolidin-2-one

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Using (5-bromothiophen-3-yl) [4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone (107 mg) described in Preparation Example 244 and (R)-4-methyloxazolidin-2-one (34 mg) and by the reaction and treatment in the same manner as in Example 1, the title compound (65 mg) was obtained.

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Using (5-bromothiophen-3-yl) [4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone (107 mg) described in Preparation Example 244 and (R)-4-methyloxazolidin-2-one (34 mg) and by the reaction and treatment in the same manner as in Example 1, the title compound (65 mg) was obtained.

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Using (5-bromopyrazin-2-yl)[4-(5-cyclopropyl-3-methylpyridin-2-yl)piperazin-1-yl]methanone (175 mg) described in Preparation Example 243 and (R)-4-methyloxazolidin-2-one (53 mg) and by the reaction and treatment in the same manner as in Example 1, the title compound (31 mg) was obtained.

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Using (6-chloropyridazin-3-yl)[4-(5-cyclopropyl-3-methylpyridin-2-yl)piperazin-1-yl]methanone (179 mg) described in Preparation Example 233 and (R)-4-methyloxazolidin-2-one (51 mg) and by the reaction and treatment in the same manner as in Example 1, the title compound (97 mg) was obtained.

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Using (6-chloropyridazin-3-yl)[4-(5-cyclopropyl-3-methylpyridin-2-yl)piperazin-1-yl]methanone (179 mg) described in Preparation Example 233 and (R)-4-methyloxazolidin-2-one (51 mg) and by the reaction and treatment in the same manner as in Example 1, the title compound (97 mg) was obtained.

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Using (5-bromopyrazin-2-yl) [4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone (130 mg) described in Preparation Example 232 and (R)-4-methyloxazolidin-2-one (35 mg) and by the reaction and treatment in the same manner as in Example 1, the title compound (110 mg) was obtained.

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Using (6-chloropyridazin-3-yl)[4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone (28 mg) described in Preparation Example 230 and (R)-4-methyloxazolidin-2-one (10 mg) and by the reaction and treatment in the same manner as in Example 1, the title compound (17 mg) was obtained.

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Using (6-chloropyridazin-3-yl)[4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone (28 mg) described in Preparation Example 230 and (R)-4-methyloxazolidin-2-one (10 mg) and by the reaction and treatment in the same manner as in Example 1, the title compound (17 mg) was obtained.

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Using methyl 4-bromomethylbenzoate (1.00 g) and (R)-4-methyloxazolidin-2-one (0.49 g) and by the reaction and treatment in the same manner as in Preparation Example 42, the title compound (0.81 g) was obtained. by the reaction and treatment in the same manner as in Preparation Example 42

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: By reaction and treatment in the same manner as in Example 201 and using 1-acetyl-3-{5-chloro-2-[4-(5-cyclopropyl-3-methylpyridin-2-yl)piperazine-1-carbonyl]phenyl}imidazolidin-2-one (344 mg) described in Preparation Example 196 and (R)-4-methyloxazolidin-2-one (61.8 mg) described in Preparation Example 25, the title compound (51.3 mg) was obtained. By reaction and treatment in the same manner as in Example 201 described in Preparation Example 25

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: By reaction and treatment in the same manner as in Example 110 and using 5-bromo-2-[4-(5-cyclopropyl-3-methylpyridin-2-yl)piperazine-1-carbonyl]benzonitrile (425 mg) described in Preparation Example 194 and (R)-4-methyloxazolidin-2-one. (121 mg) described in Preparation Example 25, the title compound (363 mg) was obtained. By reaction and treatment in the same manner as in Example 110 (121 mg) described in Preparation Example 25

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: By reaction and treatment in the same manner as in Example 149 and using 5-bromo-2-[4-(3,5-dimethylpyridin-2-yl)piperazine-1-carbonyl]benzonitrile (399 mg) described in Preparation Example 193 and (R)-4-methyloxazolidin-2-one (121 mg) described in Preparation Example 25, the title compound (326 mg) was obtained. By reaction and treatment in the same manner as in Example 149 described in Preparation Example 25